TY - JOUR
T1 - Benchmarking of survival outcomes following haematopoietic stem cell transplantation
T2 - A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
AU - Snowden, John A.
AU - Saccardi, Riccardo
AU - Orchard, Kim
AU - Ljungman, Per
AU - Duarte, Rafael F.
AU - Labopin, Myriam
AU - McGrath, Eoin
AU - Brook, Nigel
AU - de Elvira, Carmen Ruiz
AU - Gordon, Debra
AU - Poirel, Hélène A.
AU - Ayuk, Francis
AU - Beguin, Yves
AU - Bonifazi, Francesca
AU - Gratwohl, Alois
AU - Milpied, Noel
AU - Moore, John
AU - Passweg, Jakob
AU - Rizzo, J. Douglas
AU - Spellman, Stephen R.
AU - Sierra, Jorge
AU - Solano, Carlos
AU - Sanchez-Guijo, Fermin
AU - Worel, Nina
AU - Gusi, Andreu
AU - Adams, Gillian
AU - Balan, Theodor
AU - Baldomero, Helen
AU - Macq, Gilles
AU - Marry, Evelyne
AU - Mesnil, Florence
AU - Oldani, Elena
AU - Pearce, Rachel
AU - Perry, Julia
AU - Raus, Nicole
AU - Schanz, Urs
AU - Tran, Steven
AU - Wilcox, Leonie
AU - Basak, Grzegorz W.
AU - Chabannon, Christian
AU - Corbacioglu, Selim
AU - Dolstra, Harry
AU - Kuball, Jürgen
AU - Mohty, Mohamad
AU - Lankester, Arjan
AU - Montoto, Sylvia
AU - Nagler, Arnon
AU - Styczynski, Jan
AU - Yakoub-Agha, Ibrahim
AU - de Latour, Regis Peffault
AU - Kroeger, Nicolaus
AU - Brand, Ronald
AU - de Wreede, Liesbeth C.
AU - van Zwet, Erik
AU - Putter, Hein
N1 - Publisher Copyright:
© 2019, The Author(s).
PY - 2020/4/1
Y1 - 2020/4/1
N2 - In many healthcare settings, benchmarking for complex procedures has become a mandatory requirement by competent authorities, regulators, payers and patients to assure clinical performance, cost-effectiveness and safe care of patients. In several countries inside and outside Europe, benchmarking systems have been established for haematopoietic stem cell transplantation (HSCT), but access is not universal. As benchmarking is now integrated into the FACT-JACIE standards, the EBMT and JACIE established a Clinical Outcomes Group (COG) to develop and introduce a universal system accessible across EBMT members. Established systems from seven European countries (United Kingdom, Italy, Belgium, France, Germany, Spain, Switzerland), USA and Australia were appraised, revealing similarities in process, but wide variations in selection criteria and statistical methods. In tandem, the COG developed the first phase of a bespoke risk-adapted international benchmarking model for one-year survival following allogeneic and autologous HSCT based on current capabilities within the EBMT registry core dataset. Data completeness, which has a critical impact on validity of centre comparisons, is also assessed. Ongoing development will include further scientific validation of the model, incorporation of further variables (when appropriate) alongside implementation of systems for clinically meaningful interpretation and governance aiming to maximise acceptance to centres, clinicians, payers and patients across EBMT.
AB - In many healthcare settings, benchmarking for complex procedures has become a mandatory requirement by competent authorities, regulators, payers and patients to assure clinical performance, cost-effectiveness and safe care of patients. In several countries inside and outside Europe, benchmarking systems have been established for haematopoietic stem cell transplantation (HSCT), but access is not universal. As benchmarking is now integrated into the FACT-JACIE standards, the EBMT and JACIE established a Clinical Outcomes Group (COG) to develop and introduce a universal system accessible across EBMT members. Established systems from seven European countries (United Kingdom, Italy, Belgium, France, Germany, Spain, Switzerland), USA and Australia were appraised, revealing similarities in process, but wide variations in selection criteria and statistical methods. In tandem, the COG developed the first phase of a bespoke risk-adapted international benchmarking model for one-year survival following allogeneic and autologous HSCT based on current capabilities within the EBMT registry core dataset. Data completeness, which has a critical impact on validity of centre comparisons, is also assessed. Ongoing development will include further scientific validation of the model, incorporation of further variables (when appropriate) alongside implementation of systems for clinically meaningful interpretation and governance aiming to maximise acceptance to centres, clinicians, payers and patients across EBMT.
UR - http://www.scopus.com/inward/record.url?scp=85074598920&partnerID=8YFLogxK
U2 - 10.1038/s41409-019-0718-7
DO - 10.1038/s41409-019-0718-7
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 31636397
AN - SCOPUS:85074598920
SN - 0268-3369
VL - 55
SP - 681
EP - 694
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 4
ER -